What diseases does Erlotinib/Tarceva mainly treat?

Erlotinib (Erlotinib) is mainly used globally for EGFR-positive non-small cell lung cancer (NSCLC) and pancreatic cancer in combination with gemcitabine. With the popularization of genetic testing and the deepening of precision medicine, its scope of application and usage logic have been continuously improved in the past decade.

In the field of non-small cell lung cancer, erlotinib is one of the earliest widely recognized EGFR targeting drugs. It is particularly suitable for people with EGFR activating mutations, blocking abnormal proliferation of tumor cells by inhibiting the EGFR signaling pathway. Overseas guidelines list it as one of the important treatments for patients with EGFR mutations, and also emphasize the selection of the most appropriate generation of targeted drugs based on the patient's condition. Although a number of subsequent second- and third-generation EGFR drugs have been widely adopted, erlotinib still has a stable effect in some people, especially in scenarios related to the chronic management of lung cancer and long-term treatment costs.

In pancreatic cancer, erlotinib is often combined with gemcitabine, one of the few targeted combination strategies to gain regulatory approval. Its mechanism of action is believed to be related to the regulation of the epithelial growth factor pathway, thereby producing additional inhibitory effects in the complex microenvironment of pancreatic cancer. Although the overall treatment of pancreatic cancer is difficult, international studies believe that targeting mechanisms brings new possibilities to this type of highly aggressive tumors and provides additional survival benefits in some patients.

In recent years, research has also focused on new trends in resistance mechanisms, combination treatment strategies, and real-world efficacy of erlotinib. For example, in patients with locally advanced or recurrent disease, reasonable EGFR gene retyping can help determine whether to continue using erlotinib or switch to other generations of EGFR-TKI. In addition, in some people with a history of smoking, abnormal liver function, or affected drug absorption, erlotinib also has certain flexibility as a treatment option, which allows it to still maintain a high usage rate in clinical practice.

Reference: https://en.wikipedia.org/wiki/Erlotinib